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Abstract
Background: The blood based interferon-gamma release assays (IGRA) for the diagnosis of tuberculosis do not discriminate
between active TB disease and latent TB infection (LTBI). The search for distinguishing biomarkers therefore continues, as
the accurate diagnosis of tuberculosis is particularly challenging in children. IFN-c-inducible protein 10 (IP-10/CXCL10) has
recently been evaluated as a marker for active TB in adults with promising results.
Aim: To investigate this new biomarker for active TB and LTBI in paediatrics.
Method: We measured IP-10 levels using ELISA in supernatants of whole blood samples stimulated with TB-specific-
antigens and negative control antigen.
Results: IP-10 is produced in high levels following mycobacterial antigen stimulation in active TB (n=17) and LTBI (n=16)
compared to controls (n=16) and to IFN-c. The baseline levels of IP-10 are increased in active TB and in LTBI, but there is no
significant difference of stimulated levels of IP-10 between active TB and LTBI.
Conclusions: IP-10 is a biomarker for tuberculosis in children. However like IFNc, IP-10 also does not distinguish between
active TB and LTBI.
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Introduction
The diagnosis of tuberculosis (TB) in the paediatric population
remains a challenge, as TB can present similarly to many common
childhood infections and shares many symptoms with HIV.
Diagnosis is often based on contact history, clinical picture,
tuberculin skin test (TST) responses and investigations including
chest x-ray (CXR) rather than on the microbiological ‘‘gold
standard’’ [1]. The paucibacillary nature of TB in childhood limits
the microbiological yield and immunodiagnostic methods such as
the Mantoux test have been widely used in paediatrics for many
years[2]. In recent years new immunodiagnostic tests for
tuberculosis have been developed: the commercially available
Quantiferon TB Gold In Tube (Cellestis, Carnegie, Australia) and
T-SPOT TB (Oxford Immunotec, Abingdon, UK) ELISPOT
assays both measure interferon gamma (IFN-c) release by
sensitized T cells after stimulation with peptides of M. tuberculosis
specific antigens - Early Secretory Antigenic Target (ESAT)-6,
Culture Filtrate Protein (CFP)-10 plus TB7.7 in the Quantiferon
system.[3] These interferon gamma release assays (IGRA) are less
influenced than the TST by factors frequently associated with
childhood tuberculosis in developing countries, such as malnutri-
tion and HIV co-infection [4]. BCG vaccine and environmental
mycobacterial exposure are also known to influence TST results
but not IGRA[5,6]. However, the IGRA poorly distinguish
between active TB and latent TB infection (LTBI) and more
recent studies question the sensitivity of these assays, particularly in
some groups including younger children and immunocompro-
mised patients. [7,8,9].
Recent studies looking at alternative markers for diagnosis of
TB have identified a promising chemokine called IFN-c- inducible
protein 10 (IP-10) [10]. Also known as CXCL10, it is a member of
the CXC-chemokine family. Chemokines are a class of cytokines
with chemotactic properties; they have a role in mediating
leukocyte migration and activation. IP-10 is expressed in both
lymphocytes and monocytes and is involved in trafficking of Th1
lymphocytes to areas of inflammation where it binds to CXCR3 (a
receptor shared by IP-10, Mig and I-TAC)[11]. CXCR3 mRNA is
expressed in T cells alone and thus IP-10 differs from other
chemokines as it targets lymphocytes specifically and has no
activity on neutrophils. In adult studies, high levels of IP-10 have
been found in delayed type hypersensitivity reaction to Tuberculin
Purified Protein Derivative (PPD)[12], in vivo in lymph node and
lung tuberculous granulomas[13], in pleural effusions and plasma
of TB infected patients[14,15] and plasma of TB-HIV co-infected
patients diagnosed with immune reconstitution syndrome
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efficacy – serial samples show reductions in levels at 2 months in
cured TB patients, with no reduction in non-responders [15].
Levels of IP-10 are higher in those patients with systemic
symptoms such as fever and anorexia[16]. Of note IP-10 levels
in household contacts of TB infected patients, both adult and
children (85% older than 5 years), were higher than controls,
suggesting a potential value for latent TB infection (LTBI)
diagnosis [15,17]. In view of these findings in predominantly
adult studies, we investigated whether IP-10 could be a new
diagnostic biomarker for TB in children, specifically, whether it
could help in distinguishing between active TB and LTBI – a
particular challenge in the paediatric population.
Methods
Subjects
Study approval was obtained from the ethics committees of
Imperial Healthcare NHS Trusts and North West London
Hospitals Trust.
We recently conducted a research study comparing TST and
IGRA in the diagnosis of active TB and LTBI in children in
London, using the QFG-IT test and T Spot TB (submitted for
publication). In this study, we included all children between 2
months and 16 years of age who were investigated for active TB,
as well as referrals for contact tracing after exposure to a known
case of active TB. Exclusion criteria were immunocompromise,
including immunosuppressive therapy and HIV. Remaining
supernatant samples harvested from the QFG tubes and not used
for the determination of IFNc were used in this additional
investigation. For the purpose of the IP-10 study, only children
with a TST.15 and positive QFG-IT were selected for the
cohorts of active and latent TB.
Written consent for the IGRA study, including consent to use
remaining samples, was obtained from all study participants.
Definition of active TB. The diagnosis of active TB was
based on the presence of acid-fast bacilli in either gastric
washings/induced sputum or other microbiological samples, and
confirmed by growth in culture. Only children with culture proven
TB were included in this study.
Definition of latent TB infection (LTBI). For the purpose
of this study, only children with a TST.15 and positive QFG-IT
were selected for the cohort of LTBI. None of the children had
signs and symptoms of active TB and a normal chest X- ray.
Non-TB Control group. 16 children with non-TB disease
were included as controls. They were recruited from both the
outpatient department and the general paediatric ward and had a
variety of alternative diagnoses, such as fractures, urinary tract
infections, pneumonia, allergy and nephrotic syndrome. Careful
history excluded TB contact. Both IGRA were performed on all
these children and were negative in all 16.
Whole Blood Stimulation. Briefly, 1 ml of blood was drawn
directly into each vaccutainer tube provided as part of the QFG-IT
system (Cellestis, Carnegie, Australia). These tubes are already
precoated with saline (negative control), peptides of ESAT-6, CFP10
and antigen TB 7.7 (referred to as antigens/Ag for the remainder of
the paper) - and PHA (positive mitogen control). The tubes were
mixed and incubated for 20–24 hr at 37uC, when plasma was
harvested and frozen until further analysis. This plasma provided the
unstimulated and antigen (Ag) stimulated supernatant samples.
IP-10 quantification. IP-10 supernatant levels were measured
using a sandwich ELISA. Briefly, ELISA plates were coated
overnight with a monoclonal antibody for Human CXCL10/IP-10
(R&D Systems), blocked with a 2% bovine serum albumin solution,
extensively washed and test samples or recombinant human
CXCL10/IP-10 (R&D Systems) as standards were added and
incubated at room temperature for one hour. After washings, a
biotinylatedpolyclonal secondary antibody to human CXCL10/IP-
10 as (R&D Systems) was added and incubated for 1 hour at room
temperature. After washing, streptavidin conjugated HRP
(Biosource), was added for 15 minutes at room temperature,
followed by TMB. The reaction was stopped with 2 m H2SO4
and absorbance at 450 nm was measured in an ELISA reader. The
lower end of sensitivity was 50 pg/ml for this assay. The upper limit
of IP-10 for the assay was 40,000 pg/ml and readings greater than
this were set at 40,000 pg/ml for the purpose of analysis.
Calculation of Stimulation Index. For comparison
purposes, a stimulation index was calculated (ie the cytokine
concentration in plasma of antigen- stimulated whole blood
divided by the cytokine concentration of unstimulated whole
blood). A stimulation Index greater than 1.25 indicates that there
was a significant response to Ag stimulation [10].
Statistical Analysis. Significant differences between cytokine
levels were determined by the Kruskal-Wallis test. If a significant
difference was found, the Mann-Whitney U-test was used to
calculate differences between each pair of groups. Paired data was
compared by the (two-tailed) Wilcoxon signed rank test. P values
were two-sided and considered significant if ,0.05. All
calculations were performed using GraphPad Prism computer
program (GraphPad Software Inc., San Diego, CA, USA).Data
shown in the figures and tables are given as medians.
Results
The median age of the study group was 10.15 yrs (range 0.4–
16.8 yrs). The 17 children with active TB ranged from 5 to 16
years with a median age of 11.3, of whom 9 had received BCG
vaccination. The 16 children with LTBI had a median age of 10.5
years (range: 5–15.5 yrs), and 12 children were BCG vaccinated.
The median age of the control group was 5.9 years (range: 0.4–
16.8 yrs) and 8 children had received BCG-vaccine.
IP-10 measurements
The unstimulated or background levels of IP-10 were increased
in the active TB group (median 1019 pg/ml, range: 320–
5047 pg/ml) compared to control (median 320 pg/ml, range:
320–7275 pg/ml, p=0.073). However the level of IP-10 in the
LTBI group (median 2200 pg/ml, range: 320–40,000 pg/ml)
were significantly greater than either active TB (p=0.018) or
control, (median 320 pg/ml, p=0.0017). (Figure 1a)
The TB specific antigen stimulated samples demonstrated
highly significant differences between active TB (median
9544 pg/ml, range: 1386–40,000 pg/ml) and LTBI (median
19350 pg/ml, range: 2200–40,000 pg/ml, p=0.004) compared
with the control group (median 536 pg/ml, range: 320–
40,000 pg/ml, p=0.0085). (Figure 1b) When comparing the
active TB and LTBI cases, there was a greater increase in the
antigen-stimulated samples from the patients with LTBI (median
19350 pg/ml) than in the patients with active TB (median
9544 pg/ml); however, this was not significant (p=0.85).
In the patients with active TB, levels of IP-10 were found to be
significantly increased in the TB specific antigen stimulated
samples (median 9544 pg/ml, range: 2535–40,000 pg/ml) as
compared to the unstimulated or background samples (median
1019 pg/ml, 433–4308 pg/ml; p,0.0003) (Figure 1a).
A significant increase in IP-10 levels following antigen
stimulation was also detected in the samples from patients with
LTBI (median 19350 pg/ml, 2200–40,000 pg/ml, p,0.0245,
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due to the higher baseline levels.
This antigen- stimulated increase in IP-10 was also noted in the
control group, (median increased from 320 pg/ml to 536 pg/ml;
p=0.0234) but significantly lower than in active TB. This is
largely due to one patient having a very high level (40,000 pg/ml)
following antigen stimulation.
Levels of IP-10 compared with IFN-c
The levels of IP-10 were compared to the previously measured
levels of IFN-c in the same patients using the QFG-ELISA system.
In all three groups, there were significantly higher levels of IP-10
than of IFN-c following antigen stimulation (Control - IFNc
median 7.25 pg/ml, range 3.5–46.5 pg/ml; IP-10 median
536 pg/ml, range: 320–40,000 pg/ml:p=0.0001; LTBI - IFNc
median 2205 pg/ml, range 60–31084 pg/ml; IP-10 median
19350 pg/ml, range 2,200–40,000 pg/ml, p=0.0047: Active TB
- median IFNc 1124.5 pg/ml, range 10–11928.5 pg/ml; IP-10
median 9544 pg/ml, range 1386–40,000 pg/ml, p=0.0011:
(Figure 2). In the group with LTBI, the levels of both IP-10 and
IFN-c were higher than in patients with active TB (IP-10 p=0.85;
IFNc p=0.05).
Stimulation Index
Figure 3 shows that the stimulation index (SI) of IP-10 in both
active (median SI: 9.4, range: 1–125) and latent TB groups
(median SI: 8.8, range: 0.32–68.7) are greater than in the control
group (median SI: 1.7, range 0–125). This is significant in the
active cases (p=0.04), but not the LTBI cases (p=0.23). There is
only a slight difference in stimulation index between active and
latent TB (p=0.09).
The stimulation index was also used to compare IFN-c and IP-
10 in all three groups of patients (Figure 3). There was no
difference between the IP-10 and IFNc stimulation indices in the
control groups, but IFN-c has a significantly higher stimulation
index than IP-10 in both the active TB (median SI IFNc: 112.5,
Figure 1. Concentration of IP-10 (pg/ml) in supernatants from: a) whole blood samples incubated with negative control antigen
(background); b.) whole blood samples incubated with TB-specific antigens and negative control antigen, of children with active
TB (n=17), LTBI (n=16) and a control group (n=16). Horizontal lines indicate median values. Controls are represented by #, active TB by n,
and LTBI by %. Open symbols represent unstimulated, closed symbols represent antigen-stimulated samples.
doi:10.1371/journal.pone.0003901.g001
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and latent TB groups (median SI IFNc: 271, range: 1.5–16331,
median SI IP-10: 8.8, range: 0.32–68.7; p,0.0017).
Discussion
This is the first published study comparing the use of IP-10 as a
biomarker for active and latent tuberculosis in children. Although
we have demonstrated that IP-10 is a marker for tuberculosis –
active and latent - in children, we did not find it to be
discriminative between the two disease states.
Chemokines are believed to play a role in the pathogenesis of
tuberculosis, specifically in granuloma formation[18]. In particu-
lar, raised levels of IP-10 are found in adult studies of patients with
active TB[10]. Elevated levels have also been noted in household
contacts of patients with active TB[15]. Many of these studies were
measuring the unstimulated plasma level of IP-10 in confirmed
cases of TB[19]. In our study we noted a high background level of
IP-10, confirming this previously published work. It is noteworthy
that the background level of IP-10 is significantly greater in LTBI
than active TB, possibly due to a chronic state of inflammation as
the immune system attempts to control TB infection. Alternatively,
an immunosuppressive effect of active TB, modifying cytokine
responses might also explain the differences seen. It is unclear at
this stage whether the background levels of IP-10 could carry a
prognostic value for the development of active TB from latent TB.
We showed that IP-10 is produced in high levels following MTB
antigen-specific stimulation of whole blood in both active TB and
LTBI cases, demonstrating its potential as a biomarker for MTB in
children. Ruhwald et al reported similar findings in adults with
culture positive tuberculosis[10], and in children with presumed
latent TB infection[17], but there are no published data for active
TB in a paediatric population. The paediatric study by Ruhwald
included 97 household contacts under 15 years of age
(85%.5 yrs) and compared IP-10 levels in child contacts of
smear positive adults with those in both smear negative contacts
and a control group. A significant increase in IP-10 was found in
the smear positive contact group. However, these children did not
have active TB, as this study was essentially a household contact
investigation. There was good correlation between the QFG-IT
Figure 2. IFN-c and IP-10 levels (pg/ml) in Antigen stimulated samples of patients with active and latent TB and a control group.
Horizontal lines indicate median values. Controls are represented by #, active TB by n, and LTBI by %. Open symbols represent IP-10, closed
symbols represent IFNc samples.
doi:10.1371/journal.pone.0003901.g002
Figure 3. Stimulation index of IP-10 and IFN-c in active TB, LTBI and a control group. Horizontal lines indicate medians. Controls are
represented by #, active TB by n, and LTBI by %. Open symbols represent IP-10, closed symbols represent IFNc samples.
doi:10.1371/journal.pone.0003901.g003
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k=0.64) [17]. Age ranges in both the Ruhwald study and our own
study were similar and produced comparable results for LTBI.
In our study, IP-10 was produced in significantly higher levels
than IFN-c, in response to MTB antigens. IFN-c producing T-
cells are known to induce IP-10 production in primary exposure to
TB. In the mouse model, IP-10 is induced by IL-23 and IL-17
producing T-cells in a recall response to MTB infection in the
lung, independent of IFN-c production [20]. IL-23/IL-17
secreting T-cells are known to establish IFN-c producing T-cells
following initiation by TGF-b and IL-6[20]. These regulatory
cytokines are likely to be key players in granuloma stabilisation
and therefore latent TB; induction by both IFN-c-producing and
IL-17-producing T-cells may explain why the levels of IP-10 are
greater in latent TB than active TB.
The stimulation index indicates a positive response to the
specific MTB antigens as opposed to generalised activation of
cytokine- producing cells. The stimulation index of IP-10 was
notably lower than that of IFN-c, despite the higher levels of
cytokines produced. This is due to the higher background level of
IP-10 in unstimulated samples, particularly noticeable in the latent
TB cases as discussed above.
IP-10 levels are increased in patients with inflammatory states
such as autoimmune disease (systemic lupus erythematosus,
thyroid disease), acute coronary syndrome, cerebral malaria and
allergy[21,22,23,24]. In the control group in our study, one patient
in particular was found to have very high levels of IP-10. It is
probable that IP-10 is mainly a marker of inflammation and
therefore too non-specific to be a stand-alone biomarker for TB
infection. However it may still have a role as part of a panel of
diagnostic markers.
IFN-c is the key cytokine produced in response to TB antigens
following TB exposure causing either active or latent TB and this
observation forms the basis of the IGRA. However, IGRA do not
distinguish between active TB and LTBI. It is interesting to note
that although we found a higher IFNc stimulation index in LTBI
than in active TB in our study, unfortunately the difference is not
significant and therefore not useful as a diagnostic test. A difference
in IFNc levels in active TB and LTBI has been noted before and
some groups suggest a role for CD4
+CD25
highFoxP3
+ T-cells in
suppressing IFN-c responsestoa varietyofTB antigensinactiveTB
[25]. An alternative hypothesis is that IFN-c producing CD4
+ T
cells are sequestered at the tissue site of infection, rather than in the
blood, causing a paradoxically low level of IFN-c production to
antigen stimulation. This may also explain the lower levels of IP-10
in active TB compared to latent TB.
The main limitation of this study is the small sample size, which
could potentially result in a type II error in the statistical analysis.
However, we think, that this is unlikely, as all of the children in
each group were very well characterised, thus the results represent
a trend that provides direction for further studies. The children
with active and LTBI all had TST.15 and positive IGRA tests,
hence strong evidence of mycobacterial infection. We deliberately
selected these well-characterised phenotypes in order to directly
compare the stimulation of IP-10 with IFN-c production. This
could have led to bias in the IP-10 results as its production can be
induced by IFN-c. It would be interesting to compare IP-10 and
IFNc levels also in those children with clinically diagnosed TB and
negative IGRA.
Although IP-10 does not appear to be sensitive or specific
enough to supersede IGRA as tools for TB diagnosis, or to
distinguish between active TB and LTBI, a number of conclusions
can be drawn from our study: the supernatants of the Quantiferon
Gold-In-Tube assays are a useful and robust resource for
investigation of further proposed biomarkers, and we are currently
investigating other cytokines as potential biomarkers to distinguish
between active TB and LTBI using this sample bank. The levels of
IP-10 in unstimulated blood of LTBI patients may have diagnostic
and prognostic value for further investigation, and higher levels
may indicate a potentially protective mechanism for the
development of LTBI rather than active TB. Of course, only
prospective evaluation of such a biomarker could confirm this
hypothesis.
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